CN102088974A - 用tlr7活化剂对膀胱疾病的治疗 - Google Patents

用tlr7活化剂对膀胱疾病的治疗 Download PDF

Info

Publication number
CN102088974A
CN102088974A CN2009801124117A CN200980112411A CN102088974A CN 102088974 A CN102088974 A CN 102088974A CN 2009801124117 A CN2009801124117 A CN 2009801124117A CN 200980112411 A CN200980112411 A CN 200980112411A CN 102088974 A CN102088974 A CN 102088974A
Authority
CN
China
Prior art keywords
acid
carbon atoms
alkyl
groups
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2009801124117A
Other languages
English (en)
Chinese (zh)
Inventor
D·A·卡森
L·M·莱尼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Telormedix SA
University of California San Diego UCSD
Original Assignee
Telormedix SA
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Telormedix SA, University of California San Diego UCSD filed Critical Telormedix SA
Publication of CN102088974A publication Critical patent/CN102088974A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN2009801124117A 2008-02-07 2009-02-06 用tlr7活化剂对膀胱疾病的治疗 Pending CN102088974A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2699908P 2008-02-07 2008-02-07
US61/026,999 2008-02-07
PCT/US2009/000771 WO2009099650A2 (en) 2008-02-07 2009-02-06 Treatment of bladder diseases with a tlr7 activator

Publications (1)

Publication Number Publication Date
CN102088974A true CN102088974A (zh) 2011-06-08

Family

ID=40939077

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2009801124117A Pending CN102088974A (zh) 2008-02-07 2009-02-06 用tlr7活化剂对膀胱疾病的治疗

Country Status (12)

Country Link
US (1) US20090202626A1 (enExample)
EP (1) EP2259788A4 (enExample)
JP (2) JP2011511073A (enExample)
KR (1) KR20100137449A (enExample)
CN (1) CN102088974A (enExample)
AU (1) AU2009210655B2 (enExample)
BR (1) BRPI0907907A2 (enExample)
CA (1) CA2713438A1 (enExample)
EA (1) EA201001264A1 (enExample)
IL (1) IL207246A0 (enExample)
MX (1) MX2010008697A (enExample)
WO (1) WO2009099650A2 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104245695A (zh) * 2012-02-08 2014-12-24 爱尔兰詹森研发公司 用于治疗病毒性感染的哌啶基-嘧啶衍生物
CN106456630A (zh) * 2014-01-10 2017-02-22 尤罗根制药有限公司 用于治疗膀胱原位癌用途的包括咪喹莫特的药物组合物
WO2021093779A1 (zh) * 2019-11-11 2021-05-20 苏州泽璟生物制药股份有限公司 咪唑并喹啉取代磷酸酯类激动剂及其制备方法和应用

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101304748A (zh) 2005-08-22 2008-11-12 加利福尼亚大学董事会 Tlr激动剂
AU2007257423B8 (en) 2006-05-31 2012-02-16 The Regents Of The University Of California Purine analogs
PL2125007T3 (pl) 2007-02-07 2014-07-31 Univ California Koniugaty syntetycznych agonistów TLR i ich zastosowania
EP2316032A1 (en) * 2008-08-20 2011-05-04 INSERM - Institut National de la Santé et de la Recherche Médicale Methods for predicting the response to anti-cancer treatment with an agonist of tlr7 or an agonist of tlr8
WO2010088924A1 (en) 2009-02-06 2010-08-12 Telormedix Sa Pharmaceutical compositions comprising imidazoquinolin(amines) and derivatives thereof suitable for local administration
EP2607365A1 (en) 2009-02-11 2013-06-26 The Regents of The University of California Toll-like receptor modulators and treatment of diseases
US20120083473A1 (en) 2010-09-21 2012-04-05 Johanna Holldack Treatment of conditions by toll-like receptor modulators
KR101250419B1 (ko) 2010-12-16 2013-04-05 강원대학교산학협력단 Ｔｌｒ 작동제를 포함하는 유방암 방사선 치료 보조제
PH12013502033A1 (en) 2011-04-08 2014-01-06 Janssen Sciences Ireland Uc Pyrimidine derivatives for the treatment of viral infections
JP6349256B2 (ja) 2011-11-09 2018-06-27 ヤンセン・サイエンシズ・アイルランド・ユーシー ウイルス感染の治療のためのプリン誘導体
HRP20161125T1 (hr) 2012-07-13 2016-11-18 Janssen Sciences Ireland Uc Makrociklički purini za liječenje virusnih infekcija
CN112587658A (zh) 2012-07-18 2021-04-02 博笛生物科技有限公司 癌症的靶向免疫治疗
DK2906563T3 (en) 2012-10-10 2018-06-06 Janssen Sciences Ireland Uc PYRROLO [3,2-D] PYRIMIDINE DERIVATIVES FOR TREATING VIRUS INFECTIONS AND OTHER DISEASES
NZ706226A (en) 2012-11-16 2019-09-27 Janssen Sciences Ireland Uc Heterocyclic substituted 2-amino-quinazoline derivatives for the treatment of viral infections
CN105189468B (zh) 2013-02-21 2018-10-30 爱尔兰詹森科学公司 用于治疗病毒性感染的2-氨基嘧啶衍生物
PL2978429T3 (pl) 2013-03-29 2017-08-31 Janssen Sciences Ireland Uc Deazapurynony makrocykliczne do leczenia infekcji wirusowych
KR102280559B1 (ko) 2013-05-24 2021-07-22 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 바이러스 감염 및 추가적인 질환의 치료를 위한 피리돈 유도체
NO3030563T3 (enExample) 2013-06-27 2018-01-06
AU2014298540B2 (en) 2013-07-30 2018-08-09 Janssen Sciences Ireland Uc Thieno[3,2-d]pyrimidines derivatives for the treatment of viral infections
SG11201605449YA (en) * 2014-01-10 2016-08-30 Birdie Biopharmaceuticals Inc Compounds and compositions for immunotherapy
EP3091978B1 (en) * 2014-01-10 2021-08-18 Urogen Pharma Ltd. Pharmaceutical compositions comprising imiquimod for use in the treatment of carcinoma in situ of the bladder
EP4001311B1 (en) 2014-07-09 2025-11-05 Birdie Biopharmaceuticals Inc. Anti-pd-l1/pd-1 combinations for treating tumors
CN112546238A (zh) 2014-09-01 2021-03-26 博笛生物科技有限公司 用于治疗肿瘤的抗-pd-l1结合物
KR101729236B1 (ko) * 2015-06-01 2017-04-21 (주)노터스생명과학 Tlr7 항진제를 포함하는 비만 또는 간질환 예방 및 치료용 약학 조성물
CN115350279A (zh) 2016-01-07 2022-11-18 博笛生物科技有限公司 用于治疗肿瘤的抗-her2组合
CN106943596A (zh) 2016-01-07 2017-07-14 博笛生物科技（北京）有限公司 用于治疗肿瘤的抗-cd20组合
CN106943597A (zh) 2016-01-07 2017-07-14 博笛生物科技（北京）有限公司 用于治疗肿瘤的抗-egfr组合
US11697851B2 (en) 2016-05-24 2023-07-11 The Regents Of The University Of California Early ovarian cancer detection diagnostic test based on mRNA isoforms
EP3478688A1 (en) 2016-07-01 2019-05-08 Janssen Sciences Ireland Unlimited Company Dihydropyranopyrimidines for the treatment of viral infections
EP3519406B1 (en) 2016-09-29 2022-02-23 Janssen Sciences Ireland Unlimited Company Pyrimidine prodrugs for the treatment of viral infections and further diseases
CN118515666A (zh) 2017-04-27 2024-08-20 博笛生物科技有限公司 2-氨基-喹啉衍生物
US11517567B2 (en) 2017-06-23 2022-12-06 Birdie Biopharmaceuticals, Inc. Pharmaceutical compositions
TW201945003A (zh) 2018-03-01 2019-12-01 愛爾蘭商健生科學愛爾蘭無限公司 ２，４－二胺基喹唑啉衍生物及其醫學用途
ES2947713T3 (es) 2019-06-13 2023-08-17 Hollister Inc Productos de catéter urinario reutilizables
WO2020263859A1 (en) 2019-06-25 2020-12-30 Hollister Incorporated Reusable urinary catheter products

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040265351A1 (en) * 2003-04-10 2004-12-30 Miller Richard L. Methods and compositions for enhancing immune response
WO2007024707A2 (en) * 2005-08-22 2007-03-01 The Regents Of The University Of California Tlr agonists

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL73534A (en) * 1983-11-18 1990-12-23 Riker Laboratories Inc 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
US4938949A (en) * 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
US5238944A (en) * 1988-12-15 1993-08-24 Riker Laboratories, Inc. Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine
US5736553A (en) * 1988-12-15 1998-04-07 Riker Laboratories, Inc. Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo 4,5-C!quinolin-4-amine
US5037986A (en) * 1989-03-23 1991-08-06 Minnesota Mining And Manufacturing Company Olefinic 1H-imidazo[4,5-c]quinolin-4-amines
US4929624A (en) * 1989-03-23 1990-05-29 Minnesota Mining And Manufacturing Company Olefinic 1H-imidazo(4,5-c)quinolin-4-amines
NZ232740A (en) * 1989-04-20 1992-06-25 Riker Laboratories Inc Solution for parenteral administration comprising a 1h-imidazo(4,5-c) quinolin-4-amine derivative, an acid and a tonicity adjuster
DE69108920T2 (de) * 1990-10-05 1995-11-30 Minnesota Mining And Mfg. Co., Saint Paul, Minn. Verfahren zur herstellung von imidazo[4,5-c]chinolin-4-aminen.
US5175296A (en) * 1991-03-01 1992-12-29 Minnesota Mining And Manufacturing Company Imidazo[4,5-c]quinolin-4-amines and processes for their preparation
IL105325A (en) * 1992-04-16 1996-11-14 Minnesota Mining & Mfg Immunogen/vaccine adjuvant composition
US5395937A (en) * 1993-01-29 1995-03-07 Minnesota Mining And Manufacturing Company Process for preparing quinoline amines
US5352784A (en) * 1993-07-15 1994-10-04 Minnesota Mining And Manufacturing Company Fused cycloalkylimidazopyridines
US5648516A (en) * 1994-07-20 1997-07-15 Minnesota Mining And Manufacturing Company Fused cycloalkylimidazopyridines
US5525606A (en) * 1994-08-01 1996-06-11 The United States Of America As Represented By The Department Of Health And Human Services Substituted 06-benzylguanines and 6(4)-benzyloxypyrimidines
DE19505168A1 (de) * 1995-02-16 1996-08-22 Boehringer Mannheim Gmbh Spezifische Lipidkonjugate von Nucleosid-Diphosphonaten und deren Verwendung als Arzneimittel
US5624677A (en) * 1995-06-13 1997-04-29 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
US5741908A (en) * 1996-06-21 1998-04-21 Minnesota Mining And Manufacturing Company Process for reparing imidazoquinolinamines
US5693811A (en) * 1996-06-21 1997-12-02 Minnesota Mining And Manufacturing Company Process for preparing tetrahdroimidazoquinolinamines
DE19637209B4 (de) * 1996-09-12 2006-12-14 Siemens Ag Verfahren zum Steuern des Antriebsstrangs eines Kraftfahrzeugs und integrierte Antriebsstrangsteuerung
IL129319A0 (en) * 1996-10-25 2000-02-17 Minnesota Mining & Mfg Immune response modifier compounds for treatment of TH2 mediated and related diseases
WO1999024432A1 (fr) * 1997-11-12 1999-05-20 Mitsubishi Chemical Corporation Derives de purine et medicament les renfermant en tant qu'ingredient actif
KR100613634B1 (ko) * 1997-11-28 2006-08-18 다이닛본 스미토모 세이야꾸 가부시끼가이샤 신규한 복소환 화합물
US7001609B1 (en) * 1998-10-02 2006-02-21 Regents Of The University Of Minnesota Mucosal originated drug delivery systems and animal applications
US6486168B1 (en) * 1999-01-08 2002-11-26 3M Innovative Properties Company Formulations and methods for treatment of mucosal associated conditions with an immune response modifier
US20020058674A1 (en) * 1999-01-08 2002-05-16 Hedenstrom John C. Systems and methods for treating a mucosal surface
SK287112B6 (sk) * 1999-01-08 2009-12-07 3M Innovative Properties Company Použitie zlúčeniny modifikujúcej imunitnú odpoveď pri liečení cervikálnej dysplázie
CZ27399A3 (cs) * 1999-01-26 2000-08-16 Ústav Experimentální Botaniky Av Čr Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv
EP1244668B1 (en) * 2000-01-07 2006-04-05 Universitaire Instelling Antwerpen Purine derivatives, process for their preparation and use thereof
US6533645B2 (en) * 2000-01-18 2003-03-18 Applied Materials, Inc. Substrate polishing article
US6733764B2 (en) * 2000-06-14 2004-05-11 Alain Martin Immunostimulator anti-cancer compounds and methods for their use in the treatment of cancer
WO2002023186A2 (en) * 2000-09-15 2002-03-21 Virco Bvba System and method for optimizing drug therapy for the treatment of diseases
AU2002211602A1 (en) * 2000-10-11 2002-04-22 Johns Hopkins University Polymer controlled delivery of a therapeutic agent
US20020127224A1 (en) * 2001-03-02 2002-09-12 James Chen Use of photoluminescent nanoparticles for photodynamic therapy
PT1385823E (pt) * 2001-04-09 2007-01-31 Novartis Vaccines & Diagnostic Compostos de guanidino como agonistas do receptor de melanocortina-4 (r-mc4)
JP4331944B2 (ja) * 2001-04-17 2009-09-16 大日本住友製薬株式会社 新規アデニン誘導体
KR100883292B1 (ko) * 2001-06-29 2009-02-11 씨브이 쎄러퓨틱스, 인코포레이티드 Ａ２ｂ 아데노신 수용체 길항제로서의 퓨린 유도체
WO2003037860A2 (en) * 2001-10-30 2003-05-08 Conforma Therapeutics Corporation Purine analogs having hsp90-inhibiting activity
TWI349671B (en) * 2002-09-27 2011-10-01 Dainippon Sumitomo Pharma Co Novel adenine derivative and its use
WO2004066947A2 (en) * 2003-01-28 2004-08-12 Shanghai Sunway Biotech Co., Ltd. Hyperthermia oncolysis co-therapy
WO2005016235A2 (en) * 2003-04-14 2005-02-24 The Regents Of The University Of California Combined use of impdh inhibitors with toll-like receptor agonists
US20050059613A1 (en) * 2003-07-08 2005-03-17 Bahram Memarzadeh Compositions and methods for the enhanced uptake of therapeutic agents through the bladder epithelium
US20070161582A1 (en) * 2003-08-08 2007-07-12 Dusan Mijikovic Pharmaceutical compositions and methods for metabolic modulation
WO2005025583A2 (en) * 2003-09-05 2005-03-24 Anadys Pharmaceuticals, Inc. Tlr7 ligands for the treatment of hepatitis c
US7138401B2 (en) * 2003-09-18 2006-11-21 Conforma Therapeutics Corporation 2-aminopurine analogs having HSP90-inhibiting activity
FR2863890B1 (fr) * 2003-12-19 2006-03-24 Aventis Pasteur Composition immunostimulante
EP1722762A2 (en) * 2004-03-02 2006-11-22 Massachusetts Institute of Technology Nanocell drug delivery system
WO2005092893A1 (ja) * 2004-03-26 2005-10-06 Dainippon Sumitomo Pharma Co., Ltd. ９置換−８−オキソアデニン化合物
WO2006054129A1 (en) * 2004-11-19 2006-05-26 Institut Gustave Roussy Improved treatment of cancer by double-stranded rna
WO2006065234A1 (en) * 2004-12-10 2006-06-22 University Of Pittsburgh Use of lipid and hydrogel vehicles for treatment and drug delivery
US20070292418A1 (en) * 2005-04-26 2007-12-20 Eisai Co., Ltd. Compositions and methods for immunotherapy
EP1939201A4 (en) * 2005-09-22 2010-06-16 Dainippon Sumitomo Pharma Co NEW ADENINE CONNECTION
JPWO2007034817A1 (ja) * 2005-09-22 2009-03-26 大日本住友製薬株式会社 新規アデニン化合物
US20070100146A1 (en) * 2005-11-03 2007-05-03 Trevor Dzwiniel Process for the preparation of imidazo[4,5-c]-quinolin-4-amines
AU2007257423B8 (en) * 2006-05-31 2012-02-16 The Regents Of The University Of California Purine analogs
CA2656427C (en) * 2006-07-07 2014-12-09 Gilead Sciences, Inc. Modulators of toll-like receptor 7
CL2007002866A1 (es) * 2006-10-04 2008-07-04 Pharmacopeia Inc Compuestos derivados de 6-sustituidos-2-(bencimidazolil) purina y purinona; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de enfermedades autoinmunes, enfermedad inflamatoria, enfermedad mediada por m
US7902187B2 (en) * 2006-10-04 2011-03-08 Wyeth Llc 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression
PL2125007T3 (pl) * 2007-02-07 2014-07-31 Univ California Koniugaty syntetycznych agonistów TLR i ich zastosowania
TWI434849B (zh) * 2007-06-29 2014-04-21 Gilead Sciences Inc 類鐸（Ｔｏｌｌ－ｌｉｋｅ）受體７之調節劑
US20090099212A1 (en) * 2007-10-16 2009-04-16 Jeff Zablocki A3 adenosine receptor antagonists
EP2607365A1 (en) * 2009-02-11 2013-06-26 The Regents of The University of California Toll-like receptor modulators and treatment of diseases
EA020488B1 (ru) * 2009-10-22 2014-11-28 Джилид Сайэнс, Инк. Производные пурина или деазапурина для применения при лечении вирусных инфекций и других заболеваний
US20120003298A1 (en) * 2010-04-30 2012-01-05 Alcide Barberis Methods for inducing an immune response
CN103221067B (zh) * 2010-04-30 2016-01-06 泰勒麦迪克斯公司 磷脂药物类似物
CN105999275A (zh) * 2010-09-01 2016-10-12 诺华有限公司 免疫增强剂吸附不溶性金属离子
US20120083473A1 (en) * 2010-09-21 2012-04-05 Johanna Holldack Treatment of conditions by toll-like receptor modulators

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040265351A1 (en) * 2003-04-10 2004-12-30 Miller Richard L. Methods and compositions for enhancing immune response
WO2007024707A2 (en) * 2005-08-22 2007-03-01 The Regents Of The University Of California Tlr agonists

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104245695A (zh) * 2012-02-08 2014-12-24 爱尔兰詹森研发公司 用于治疗病毒性感染的哌啶基-嘧啶衍生物
CN104245695B (zh) * 2012-02-08 2017-06-06 爱尔兰詹森科学公司 用于治疗病毒性感染的哌啶基‑嘧啶衍生物
CN106456630A (zh) * 2014-01-10 2017-02-22 尤罗根制药有限公司 用于治疗膀胱原位癌用途的包括咪喹莫特的药物组合物
WO2021093779A1 (zh) * 2019-11-11 2021-05-20 苏州泽璟生物制药股份有限公司 咪唑并喹啉取代磷酸酯类激动剂及其制备方法和应用

Also Published As

Publication number Publication date
WO2009099650A3 (en) 2009-10-22
US20090202626A1 (en) 2009-08-13
JP2011511073A (ja) 2011-04-07
BRPI0907907A2 (pt) 2015-07-28
AU2009210655A1 (en) 2009-08-13
EP2259788A4 (en) 2011-03-16
EA201001264A1 (ru) 2011-04-29
JP2014129425A (ja) 2014-07-10
MX2010008697A (es) 2010-12-07
EP2259788A2 (en) 2010-12-15
KR20100137449A (ko) 2010-12-30
AU2009210655B2 (en) 2013-08-15
WO2009099650A2 (en) 2009-08-13
WO2009099650A4 (en) 2010-01-14
CA2713438A1 (en) 2009-08-13
IL207246A0 (en) 2010-12-30

Similar Documents

Publication Publication Date Title
AU2009210655B2 (en) Treatment of bladder diseases with a TLR7 activator
JP5425642B2 (ja) 合成ｔｌｒアゴニストの結合体およびそのための使用
JP5923581B2 (ja) 局所投与に好適なイミダゾキノリン（アミン）及びその誘導体を含む医薬組成物
CN106061261B (zh) 治疗化合物的结晶形式及其用途
CN105143174A (zh) 治疗帕金森疾病的新型高穿透力药物和医药组合物
JP2021514345A (ja) Ｃｄ４７シグナル伝達経路の阻害剤としての１，２，４−オキサジアゾール化合物
CN107929743B (zh) 治疗肺部疾病的高穿透力前药组合物和医药组合物
JP6494528B2 (ja) フッ化インテグリンアンタゴニスト
JP2024041834A (ja) 新規組成物及び治療方法
KR20210027381A (ko) 신규 면역조절 소분자
CA3026763A1 (en) Topical formulations of pde-4 inhibitors and their methods of use
JP7596296B2 (ja) 炎症性障害を治療するための化合物および方法
CN108289858A (zh) 用于治疗肿瘤性皮肤疾病的瑞喹莫特局部可注射组合物
KR20230155047A (ko) 나노입자-코어 및 표면에 코팅된 CpG-올리고디옥시뉴클레오티드를 포함하는 항암용 조성물
JP4232866B2 (ja) 細胞障害抑制剤
TW201219037A (en) Prophylactic and/or therapeutic agent against lymphedema
JP2022520671A (ja) 耳障害を治療するためのバルプロ酸化合物及びｗｎｔ作動薬
US10918641B2 (en) Use of MTAP inhibitors for the treatment of lung disease
WO2023134732A9 (en) Prevention or treatment of cardiovascular diseases with high penetration prodrugs of aspirin and other nsaids
US20250120928A1 (en) Suberoylanilide hydroxamic acid (saha) drugs, conjugates, and nanoparticles, and methods of use thereof
US20210038742A1 (en) Conjugation of tlr7 agonist to nano-materials enhances the agonistic activity
JP2000072677A (ja) 抗真菌性組成物
HK1215017B (zh) 治疗帕金森疾病的新型高穿透力药物及其药物组合物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20110608